Connect Biopharma’s Partner Simcere Submits New Drug Application for Atopic Dermatitis in China

Connect Biopharma’s Partner Company to Submit its New Drug Application

Announcement

Connect Biopharma Holdings Limited, a biopharmaceutical company known for its unique care for the treatment of inflammatory disease, has proudly announced that its partner company, and a China-licensed company Simcere pharmaceutical co. Ltd submitted its new drug application for rademikibart to the National Medical Products Administration of China (NMPA) for the treatment of atopic dermatitis (AD) in adolescents and adults. The CBP-201 (rademikibart) is a lead product candidate of Connect Biopharma. The company is currently organizing worldwide studies of rafemikibart to cure COPD and asthma. This can lead to a big support from this company’s end to its collaborator company’s new drug application.

About the Partnership

In the year 2023, Simcere and Connect signed a collaborative and licensing agreement for rademikibart in China. The agreement states that Simcere received the complete right to commercialize, developand manufacture Rademikibart covering all indications in Greater China. Also, covering Taiwan, mainland China, Hong Kong, and Macau areas. Connect has ‘keep rights’ in all other markets.

Under the agreement, Connect will receive profit payments of the remaining amount of the $110 million only on the success of the specific development, commercial, or regulatory milestones. Connect will also receive royalties at a fixed percentage rate (up to a low double-digit percentage) on net sales in Greater China. China’s AD market provides various opportunities (due to its 70 million patients with AD).

The benefits and opportunities through this partnership can be seen through the submission of the new drug application.  Connect can explore and even stand a chance to expand in the china healthcare market via Simcere. Simcere’s recent submission’s outcome will open a new scope or introduction to the healthcare market. Both companies are highly contributing to the market with their discoveries and innovations. Further, the additional transformation is pending with the new drug application. Moreover, the studies related to the new drug application will be the main focus after its approval.

Views and Statements

CEO and Director of Connect Biopharma, Phd, Barry Quart said, “Simcere has been constantly making progress in advancing rademikibart in China, that is our excellent best-in-class IL-4Ra antibody. Atopic dermatitis is the fastest-growing market in China, and Rademikibart can contribute to improving the condition of millions of patients. Along with Simcere, we were able to stay committed and focused on advancing rademikibart for the treatment of several inflammatory diseases that consist including asthma, chronic obstructive pulmonary disease, and AD diseases.”